Haemonetics Corp. (NYSE:HAE) traded down 2.3% on Friday . The company traded as low as $29.76 and last traded at $29.76, with a volume of 186,287 shares changing hands. The stock had previously closed at $30.46.

Several brokerages have recently commented on HAE. Morgan Stanley reissued a “hold” rating on shares of Haemonetics Corp. in a report on Tuesday, May 3rd. BTIG Research reissued a “hold” rating on shares of Haemonetics Corp. in a report on Tuesday, April 19th. Barrington Research reduced their target price on Haemonetics Corp. from $40.00 to $32.00 and set an “outperform” rating on the stock in a report on Tuesday, May 3rd. Goldman Sachs Group Inc. raised Haemonetics Corp. from a “sell” rating to a “neutral” rating and set a $29.00 target price on the stock in a report on Monday, May 16th. Finally, Benchmark Co. reduced their target price on Haemonetics Corp. from $35.00 to $28.00 and set a “hold” rating on the stock in a report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. Haemonetics Corp. presently has a consensus rating of “Hold” and an average price target of $32.25.

The stock has a 50-day moving average of $29.37 and a 200-day moving average of $31.18. The stock’s market cap is $1.53 billion.

Haemonetics Corp. (NYSE:HAE) last released its quarterly earnings results on Monday, May 2nd. The company reported $0.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by $0.09. During the same quarter in the prior year, the company posted $0.47 earnings per share. The business had revenue of $243.20 million for the quarter, compared to analysts’ expectations of $245.08 million. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, analysts expect that Haemonetics Corp. will post $1.45 earnings per share for the current year.

Several hedge funds and institutional investors have made changes to their positions in HAE. American Capital Management Inc. boosted its position in shares of Haemonetics Corp. by 1.6% in the fourth quarter. American Capital Management Inc. now owns 703,376 shares of the company’s stock valued at $22,677,000 after buying an additional 10,920 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Haemonetics Corp. by 5.1% in the fourth quarter. Principal Financial Group Inc. now owns 344,105 shares of the company’s stock valued at $11,094,000 after buying an additional 16,768 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Haemonetics Corp. by 3.0% in the fourth quarter. New York State Common Retirement Fund now owns 55,769 shares of the company’s stock valued at $1,798,000 after buying an additional 1,600 shares in the last quarter. Comerica Bank boosted its position in shares of Haemonetics Corp. by 0.6% in the fourth quarter. Comerica Bank now owns 52,596 shares of the company’s stock valued at $1,596,000 after buying an additional 321 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Haemonetics Corp. by 1.3% in the fourth quarter. Rhumbline Advisers now owns 75,509 shares of the company’s stock valued at $2,434,000 after buying an additional 935 shares in the last quarter.

Haemonetics Corporation is a healthcare company, which provides blood management solutions to its customers. The Company’s portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.